Danaher Co. (NYSE:DHR) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. trimmed its position in shares of Danaher Co. (NYSE:DHR) by 5.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 597,368 shares of the conglomerate’s stock after selling 33,927 shares during the period. Federated Hermes Inc. owned approximately 0.08% of Danaher worth $138,195,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Drive Wealth Management LLC increased its holdings in Danaher by 3.1% in the fourth quarter. Drive Wealth Management LLC now owns 1,485 shares of the conglomerate’s stock valued at $344,000 after buying an additional 44 shares during the last quarter. Nations Financial Group Inc. IA ADV grew its stake in Danaher by 0.8% in the 1st quarter. Nations Financial Group Inc. IA ADV now owns 6,064 shares of the conglomerate’s stock worth $1,779,000 after acquiring an additional 46 shares during the period. New Hampshire Trust grew its stake in Danaher by 0.3% in the 3rd quarter. New Hampshire Trust now owns 14,438 shares of the conglomerate’s stock worth $3,582,000 after acquiring an additional 50 shares during the period. Connolly Sarah T. grew its stake in Danaher by 0.5% in the 3rd quarter. Connolly Sarah T. now owns 9,599 shares of the conglomerate’s stock worth $2,382,000 after acquiring an additional 50 shares during the period. Finally, Thrive Wealth Management LLC grew its stake in Danaher by 0.9% in the 3rd quarter. Thrive Wealth Management LLC now owns 5,496 shares of the conglomerate’s stock worth $1,364,000 after acquiring an additional 51 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Down 0.7 %

Shares of NYSE DHR traded down $1.64 during trading on Thursday, hitting $237.75. 1,771,364 shares of the company traded hands, compared to its average volume of 2,693,817. The business’s fifty day moving average is $249.28 and its 200 day moving average is $229.86. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $259.00. The firm has a market capitalization of $176.06 billion, a price-to-earnings ratio of 37.46, a P/E/G ratio of 3.65 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.68.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, beating the consensus estimate of $1.91 by $0.18. The firm had revenue of $6.41 billion during the quarter, compared to analyst estimates of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The company’s revenue for the quarter was down 10.2% on a year-over-year basis. During the same quarter last year, the business posted $2.87 EPS. Equities research analysts predict that Danaher Co. will post 7.62 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be given a dividend of $0.27 per share. The ex-dividend date is Wednesday, March 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio (DPR) is 16.90%.

Insider Activity

In related news, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the transaction, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the transaction, the senior vice president now owns 4,244 shares in the company, valued at $1,029,891.48. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Daniel Raskas sold 23,757 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,957 shares of company stock worth $8,265,802. 11.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Royal Bank of Canada boosted their price objective on shares of Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Barclays boosted their price objective on shares of Danaher from $240.00 to $260.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 10th. JPMorgan Chase & Co. lifted their target price on shares of Danaher from $250.00 to $270.00 and gave the company an “overweight” rating in a report on Wednesday, December 20th. KeyCorp lifted their target price on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Finally, StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average price target of $268.27.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.